{"title":"Buprenorphine-Naloxone Maintenance and Lactation.","authors":"Lauren M Jansson, Krystle McConnell, Martha Velez, Nancy Spencer, Munchelou Gomonit, Madeleine J Swortwood","doi":"10.1177/08903344231209304","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Breastfeeding among lactating people with opioid use disorder taking buprenorphine monotherapy is generally accepted, as low concentrations of buprenorphine and metabolites in human milk have been well-established. The use of buprenorphine-naloxone for pregnant and lactating people with opioid use disorder is expanding and there is no information available regarding the concentrations of naloxone and their metabolites in human milk to recommend the use of this combination medication during lactation.</p><p><strong>Research aims: </strong>To determine the concentrations of buprenorphine and naloxone and their primary metabolites in human milk, maternal plasma, and infant plasma, among lactating buprenorphine-naloxone maintained people and their infants.</p><p><strong>Methods: </strong>Four lactating buprenorphine-naloxone maintained people provided plasma and human milk samples on Days 2, 3, 4, 14, and 30 postpartum. Infant plasma was obtained on Day 14.</p><p><strong>Results: </strong>Concentrations of buprenorphine, norbuprenorphine and their glucuronide metabolites were present in maternal plasma and human milk at low concentrations, consistent with previous research in lactating buprenorphine monotherapy participants. Naloxone was not detected, or was detected at concentrations below the limit of quantification, in maternal plasma and in all except one human milk sample at Day 30. Naloxone was not detected or detected at concentrations below the limit of quantification in all infant plasma samples.</p><p><strong>Conclusion: </strong>Results support the use of buprenorphine-naloxone by lactating people who meet appropriate criteria for breastfeeding.</p>","PeriodicalId":15948,"journal":{"name":"Journal of Human Lactation","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Human Lactation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/08903344231209304","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/29 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"NURSING","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Breastfeeding among lactating people with opioid use disorder taking buprenorphine monotherapy is generally accepted, as low concentrations of buprenorphine and metabolites in human milk have been well-established. The use of buprenorphine-naloxone for pregnant and lactating people with opioid use disorder is expanding and there is no information available regarding the concentrations of naloxone and their metabolites in human milk to recommend the use of this combination medication during lactation.
Research aims: To determine the concentrations of buprenorphine and naloxone and their primary metabolites in human milk, maternal plasma, and infant plasma, among lactating buprenorphine-naloxone maintained people and their infants.
Methods: Four lactating buprenorphine-naloxone maintained people provided plasma and human milk samples on Days 2, 3, 4, 14, and 30 postpartum. Infant plasma was obtained on Day 14.
Results: Concentrations of buprenorphine, norbuprenorphine and their glucuronide metabolites were present in maternal plasma and human milk at low concentrations, consistent with previous research in lactating buprenorphine monotherapy participants. Naloxone was not detected, or was detected at concentrations below the limit of quantification, in maternal plasma and in all except one human milk sample at Day 30. Naloxone was not detected or detected at concentrations below the limit of quantification in all infant plasma samples.
Conclusion: Results support the use of buprenorphine-naloxone by lactating people who meet appropriate criteria for breastfeeding.
期刊介绍:
Committed to the promotion of diversity and equity in all our policies and practices, our aims are:
To provide our readers and the international communities of clinicians, educators and scholars working in the field of lactation with current and quality-based evidence, from a broad array of disciplines, including the medical sciences, basic sciences, social sciences and the humanities.
To provide student and novice researchers, as well as, researchers whose native language is not English, with expert editorial guidance while preparing their work for publication in JHL.
In each issue, the Journal of Human Lactation publishes original research, original theoretical and conceptual articles, discussions of policy and practice issues, and the following special features:
Advocacy: A column that discusses a ‘hot’ topic in lactation advocacy
About Research: A column focused on an in-depth discussion of a different research topic each issue
Lactation Newsmakers: An interview with a widely-recognized outstanding expert in the field from around the globe
Research Commentary: A brief discussion of the issues raised in a specific research article published in the current issue
Book review(s): Reviews written by content experts about relevant new publications
International News Briefs: From major international lactation organizations.